Literature DB >> 7595659

Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain.

J R Moffett1, M A Namboodiri.   

Abstract

Contradictory immunohistochemical data have been reported on the localization of N-acetylaspartylglutamate in the rat forebrain, using different carbodiimide fixation protocols and antibody purification methods. In one case, N-acetylaspartylglutamate immunoreactivity was observed in apparent interneurons throughout all allocortical and isocortical regions, suggesting possible colocalization with GABA. In another case, strong immunoreactivity was observed in numerous pyramidal cells in neocortex and hippocampus, suggesting colocalization with glutamate or aspartate. Reconciling these disparate findings is crucial to understanding the role of N-acetylaspartylglutamate in nervous system function. Antibodies to N-acetylaspartylglutamate and a structurally related molecule, N-acetylaspartate, were purified in stages, and their cross-reactivities with protein conjugates of N-acetylaspartylglutamate and N-acetylaspartate were monitored at each stage by solid-phase immunoassay. Reduction of the cross-reactivity of the anti-N-acetylaspartylglutamate antibodies of N-acetylaspartate-protein conjugates to about 1% eliminated significant staining of most pyramidal neurons in the rat forebrain. Utilizing highly purified antibodies, the distributions of N-acetylaspartylglutamate and N-acetylaspartate were examined in several major telencephalic and diencephalic regions of the rat, and were found to be distinct. N-acetylaspartylglutamate-immunoreactivity was observed in specific neuronal populations, including many groups thought to use GABA as a neurotransmitter. Among these were the globus pallidus, ventral pallidum, entopeducular nucleus, thalamic reticular nucleus, and scattered non-pyramidal neurons in all layers of isocortex and allocortex. N-acetylaspartate-immunoreactivity was more broadly distributed than N-acetylaspartylglutamate-immunoreactivity in the rat forebrain, appearing strongest in many pyramidal neurons. Although N-acetylaspartate-immunoreactivity was found in most neurons, it exhibited a great range of intensities between different neuronal types.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7595659     DOI: 10.1007/BF01181604

Source DB:  PubMed          Journal:  J Neurocytol        ISSN: 0300-4864


  23 in total

Review 1.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

2.  Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.

Authors:  Chikkathur N Madhavarao; Peethambaran Arun; John R Moffett; Sylvia Szucs; Sankar Surendran; Reuben Matalon; James Garbern; Diana Hristova; Anne Johnson; Wei Jiang; M A Aryan Namboodiri
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-22       Impact factor: 11.205

3.  Age-related glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4 T.

Authors:  Lana G Kaiser; Norbert Schuff; Nathan Cashdollar; Michael W Weiner
Journal:  Neurobiol Aging       Date:  2005-05       Impact factor: 4.673

4.  GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism.

Authors:  Emilio R Garrido Sanabria; Krystyna M Wozniak; Barbara S Slusher; Asaf Keller
Journal:  J Neurophysiol       Date:  2003-08-13       Impact factor: 2.714

5.  Reduced extrahippocampal NAA in mesial temporal lobe epilepsy.

Authors:  Susanne G Mueller; Joyce Suhy; Kenneth D Laxer; Derek L Flenniken; Jana Axelrad; Andres A Capizzano; Michael W Weiner
Journal:  Epilepsia       Date:  2002-10       Impact factor: 5.864

6.  Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II.

Authors:  Liqun Han; Jonathan D Picker; Laura R Schaevitz; Guochuan Tsai; Jiamin Feng; Zhichun Jiang; Hillary C Chu; Alo C Basu; Joanne Berger-Sweeney; Joseph T Coyle
Journal:  Synapse       Date:  2009-08       Impact factor: 2.562

7.  Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model.

Authors:  C N Madhavarao; P Arun; Y Anikster; S R Mog; O Staretz-Chacham; J R Moffett; N E Grunberg; W A Gahl; A M A Namboodiri
Journal:  J Inherit Metab Dis       Date:  2009-08-15       Impact factor: 4.982

8.  In vivo glutamate measured with magnetic resonance spectroscopy: behavioral correlates in aging.

Authors:  Natalie M Zahr; Dirk Mayer; Torsten Rohlfing; Sandra Chanraud; Meng Gu; Edith V Sullivan; Adolf Pfefferbaum
Journal:  Neurobiol Aging       Date:  2012-10-30       Impact factor: 4.673

9.  Immunohistological and electrophysiological evidence that N-acetylaspartylglutamate is a co-transmitter at the vertebrate neuromuscular junction.

Authors:  Kathryn K Walder; Steve B Ryan; Tomasz Bzdega; Rafal T Olszewski; Joseph H Neale; Clark A Lindgren
Journal:  Eur J Neurosci       Date:  2012-11-08       Impact factor: 3.386

10.  Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia.

Authors:  Daiying Zuo; Tomasz Bzdega; Rafal T Olszewski; John R Moffett; Joseph H Neale
Journal:  J Biol Chem       Date:  2012-05-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.